Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evenamide - Newron Pharmaceuticals

Drug Profile

Evenamide - Newron Pharmaceuticals

Alternative Names: NW-3509; NW-3509A

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Newron Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; NAV1.7 voltage gated sodium channel expression inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; NAV1.8 voltage gated sodium channel expression inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 5-HT2 receptor agonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase II/III Psychiatric disorders

Most Recent Events

  • 13 May 2024 Updated efficacy and adverse events data from phase II/III trial in Schizophrenia released by Newron Pharmaceuticals
  • 30 Apr 2024 Efficacy and adverse events data from phase II/III trial in Schizophrenia released by Newron Pharmaceuticals
  • 04 Jan 2024 Pooled efficacy and adverse event data from phase III 014/015 trial in Schizophrenia released by Newron Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top